Wilson’s disease-Reference-Cited by-同舟云学术

Wilson’s disease

Published:2024 Issue:5-6 Volume:152 Page:310-317
ISSN:0370-8179
Container-title:Srpski arhiv za celokupno lekarstvo
language:en
Short-container-title:Srp Arh Celok Lek

Author:

Svetel Marina¹^ORCID,Kresojevic Nikola¹^ORCID,Tomic Aleksandra¹^ORCID,Jecmenica-Lukic Milica¹^ORCID,Markovic Vladana¹^ORCID,Stankovic Iva¹^ORCID,Petrovic Igor¹,Pekmezovic Tatjana²^ORCID,Novakovic Ivana²^ORCID,Bozic Marija³^ORCID,Svetel Marko⁴,Vitkovic Jelena⁵,Dragasevic Natasa¹

Affiliation:

1. University Clinical Centre of Serbia, Neurology Clinic, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, Serbia

2. University of Belgrade, Faculty of Medicine, Belgrade, Serbia

3. University of Belgrade, Faculty of Medicine, Belgrade, Serbia + University Clinical Centre of Serbia, University Eye Hospital, Belgrade, Serbia

4. University Clinical Centre of Serbia, University Eye Hospital, Belgrade, Serbia

5. University Clinical Centre of Serbia, Neurology Clinic, Belgrade, Serbia

Abstract

Wilson?s disease (WD) is an autosomal recessive inherited disorder of copper metabolism caused by mutations in the ATP7B gene, which is located on chromosome 13q14.3. The global genetic prevalence of WD at birth is approximately 13.9?15.4 per 100,000 population. Although WD is a rare condition associated with treatment efficacy, mortality rates in patients with WD (5?6.1%) are higher than healthy controls. Prevalent features of WD include hepatic, neurologic, and psychiatric syndromes, even though various signs and symptoms of the disease have been depicted to this point. If diagnosed and treated at an early stage, WD patients would likely improve and be often largely asymptomatic for the rest of their lives. Prompt diagnosis and lifelong treatment substantially affect outcome. We aimed to summarize current knowledge about WD epidemiology, genetics, clinical manifestations, diagnostic workup, and current WD management.

Publisher

National Library of Serbia

Reference37 articles.

1. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671-85. [DOI: 10.1016/j.jhep.2011.11.007] [PMID: 22340672]

2. Beyzaei Z, Mehrzadeh A, Hashemi N, Geramizadeh B. The mutation spectrum and ethnic distribution of Wilson disease, a review. Mol Genet Metab Rep. 2023;38:101034. [DOI: 10.1016/j.ymgmr.2023.101034] [PMID: 38149214]

3. Tomić A, Dobricić V, Novaković I, Svetel M, Pekmezović T, Kresojević N, et al. Mutational analysis of ATP7B gene and the genotype-phenotype correlation in patients with Wilson’s disease in Serbia. Vojnosanit Pregl. 2013;70(5):457-62. [DOI: 10.2298/vsp1305457t] [PMID: 23789284]

4. Loudianos G, Kostic V, Solinas P, Lovicu M, Dessi V, Svetel M, et al. Characterization of the molecular defect in the ATP7B gene in Wilson disease patients from Yugoslavia. Genet Test. 2003;7(2):107-12. [DOI: 10.1089/109065703322146786] [PMID: 12885331]

5. Gao J, Brackley S, Mann JP. The global prevalence of Wilson disease from next-generation sequencing data. Genet Med. 2019;21(5):1155-63. [DOI: 10.1038/s41436-018-0309-9] [PMID: 30254379]